International Pharmaceutical Industry journal speaks with Ensera’s Chief Executive Officer, Jason Anderson, on the company’s approach to drug delivery and pharma packaging, its unique position in the supply chain, and the trends and opportunities shaping 2026 for both Ensera and the wider pharmaceutical sector.
What are Ensera’s key objectives for Pharmapack this year, and what are you hoping to take away from the event?
In a word, connections. This industry is about connections. At Ensera and Ensera Design, we’re a partner to healthcare companies, pharma companies and medical device companies. We offer a wide range of services, but not everything that’s needed. So it’s about connecting with potential customers and peers, and making sure we can most effectively serve the needs of drug companies, healthcare companies and, therefore, patients.
What trends in drug delivery and pharma packaging will impact Ensera’s customers most this year?
There are several trends impacting the industry this year. Geopolitical uncertainty cannot be ignored, and it puts companies in a tricky position. This is a critical industry for human health, so businesses need to make smart decisions to remain viable while keeping patients in mind. The challenge is knowing when and how to make changes. Supply chains may need adjustment to ensure continued success and access, but uncertainty can make it difficult to commit to change. As a result, there is an increasing need for flexibility, adaptability and sometimes very rapid modifications to supply chains, which is an area where we can be particularly helpful.
Other trends include the continued growth of weight loss drugs, particularly GLP-1 classes, including new oral solid dose versions that have major market implications. At the same time, new therapies for rare diseases are emerging, and many biosimilars are coming to market to increase access to biologics.
This combination of high-volume growth in some segments and complex, smaller-volume opportunities in others creates both challenges and opportunities. We serve both segments, with a particular focus on smaller-volume, complex situations, and we see an important role in helping get these therapies to patients.
What is Ensera’s unique position in the pharma and drug delivery device supply chain?
We’re both a manufacturing company supply chain partner and a design consultancy firm. We are Ensera Design and Ensera, bringing a full design-to-manufacturing approach.
From the design standpoint, this can start at early-stage device design if a custom delivery device is needed, including assessments, validation testing and regulatory services, and continue through commercialisation and assembly of the supply chain.
Our design business has a strong history in drug delivery devices across injectables, ventilation devices and wearable drug delivery devices. We also manufacture devices and are in the drug value chain, including final assembly of combination devices. These complementary capabilities are not common to find under one roof.
How does this add value for pharma and drug delivery companies?
Speed and flexibility are essential in times of uncertainty, particularly when getting products to market and therapies into the hands of patients. With multiple capabilities under one roof, we are able to put those pieces together within our team. Our teams know each other and can work very quickly together.
We recognise we are not the largest volume provider of the kinds of services we provide, but where speed and flexibility are really key, that’s where the uniqueness of Ensera and Ensera Design really shows.
Looking ahead to 2026, what do you see on the horizon for Ensera and for the wider pharma sector?
There’s quite a bit going on at Ensera. We continue to grow and are making investments in the business. We’re building a growing number of partnerships across the industry and a network of partners providing complementary services.
Our design and manufacturing businesses have been combined for a few years, and we continue to focus on working together as effectively as possible to bring products and solutions to market quickly.
2026 is shaping up to be an exciting year for the industry. We rebranded in October, so this is our first full year operating under the Ensera brand. A lot of focus last year went into developing that new identity, launching it, and bringing all the pieces together. Now, the focus shifts to building the brand, defining what it represents, and demonstrating its value to partners, collaborators, and the wider industry.
This gives us the opportunity to strengthen our presence in the market, expand our partnerships, and showcase the combined capabilities of Ensera and Ensera Design. It’s a very different focus compared with 2025, moving from establishing the foundation of the brand to actively leveraging it to support growth, innovation, and impact in the pharma and medical device sector.
